The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Clinical trial NCT06117644 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06117644
Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL

Non Small Cell Lung Cancer EGFR Gene Mutation Non Small Cell Lung Cancer Stage IIIA Non-small Cell Lung Cancer Stage IV

Start date: 2023-11-01
Primary completion: 2025-11-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.